Global Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor), Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Route of Administration, End-Users, Distribution Channel - Forecast 2024-2030- Product Image

Sale

Global Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor), Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Route of Administration, End-Users, Distribution Channel - Forecast 2024-2030

Report
190 Pages
March 2024
Region: Global
360iResearch™
ID: 5888905

UP TO €845EUR$875USD£723GBP OFF until Dec 31^st 2024

The Immune Checkpoint Inhibitors Market size was estimated at USD 9.47 billion in 2023, USD 10.46 billion in 2024, and is expected to grow at a CAGR of 10.82% to reach USD 19.46 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Immune Checkpoint Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Immune Checkpoint Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Immune Checkpoint Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Alphamab Oncolog, ALX Oncology Inc., Astellas Pharma Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, ImmuneSensor Therapeutics Inc., ImmunityBio, Inc., Kintor Pharmaceutical Limited, Merck KGaA, MiNK Therapeutics, Inc., NATCO Pharma Ltd., NextCure, Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Seagen Inc., SQZ Biotechnologies Company, Thermo Fisher Scientific Inc., and Xencor, Inc.

Market Segmentation & Coverage

This research report categorizes the Immune Checkpoint Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- CTLA-4 Inhibitor
- PD-1 Inhibitor
- PD-L1 Inhibitor
Indication
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Hodgkin Lymphoma
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Solid Cancer
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Specialty Clinics
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Immune Checkpoint Inhibitors Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Immune Checkpoint Inhibitors Market?
What are the technology trends and regulatory frameworks in the Immune Checkpoint Inhibitors Market?
What is the market share of the leading vendors in the Immune Checkpoint Inhibitors Market?
Which modes and strategic moves are suitable for entering the Immune Checkpoint Inhibitors Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Immune Checkpoint Inhibitors Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer across the globe
5.1.1.2. Rising government initiatives for cancer treatment and awareness programs
5.1.1.3. Growing geriatric population and adoption of unhealthy lifestyle
5.1.2. Restraints
5.1.2.1. Associated side effects, high cost and efficacy concerns of immune checkpoint inhibitors
5.1.3. Opportunities
5.1.3.1. Ongoing research activities for advanced cancer treatments
5.1.3.2. Rise in approvals of novel immune checkpoint inhibitors from regulatory bodies
5.1.4. Challenges
5.1.4.1. Presence of alternative treatment therapies for cancer
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization

6. Immune Checkpoint Inhibitors Market, by Type

6.1. Introduction
6.2. CTLA-4 Inhibitor
6.3. PD-1 Inhibitor
6.4. PD-L1 Inhibitor

7. Immune Checkpoint Inhibitors Market, by Indication

7.1. Introduction
7.2. Bladder Cancer
7.3. Breast Cancer
7.4. Cervical Cancer
7.5. Hodgkin Lymphoma
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Solid Cancer

8. Immune Checkpoint Inhibitors Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral

9. Immune Checkpoint Inhibitors Market, by End-Users

9.1. Introduction
9.2. Hospitals
9.3. Specialty Clinics

10. Immune Checkpoint Inhibitors Market, by Distribution Channel

10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies

11. Americas Immune Checkpoint Inhibitors Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Immune Checkpoint Inhibitors Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Immune Checkpoint Inhibitors Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
15.1.1. Alphamab Oncolog
15.1.2. ALX Oncology Inc.
15.1.3. Astellas Pharma Inc.
15.1.4. AstraZeneca PLC
15.1.5. Becton, Dickinson and Company
15.1.6. Bio-Rad Laboratories, Inc.
15.1.7. BioNTech SE
15.1.8. Boehringer Ingelheim International GmbH
15.1.9. Bristol-Myers Squibb
15.1.10. Dr. Reddy’s Laboratories Ltd.
15.1.11. F. Hoffmann-La Roche AG
15.1.12. Genmab A/S
15.1.13. GlaxoSmithKline PLC
15.1.14. ImmuneSensor Therapeutics Inc.
15.1.15. ImmunityBio, Inc.
15.1.16. Kintor Pharmaceutical Limited
15.1.17. Merck KGaA
15.1.18. MiNK Therapeutics, Inc.
15.1.19. NATCO Pharma Ltd.
15.1.20. NextCure, Inc.
15.1.21. Regeneron Pharmaceuticals Inc.
15.1.22. Sanofi SA
15.1.23. Seagen Inc.
15.1.24. SQZ Biotechnologies Company
15.1.25. Thermo Fisher Scientific Inc.
15.1.26. Xencor, Inc.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing

List of Figures

FIGURE 1. IMMUNE CHECKPOINT INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2022 VS 2030
FIGURE 3. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. IMMUNE CHECKPOINT INHIBITORS MARKET DYNAMICS
FIGURE 7. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 8. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 10. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
FIGURE 12. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2022 VS 2030 (%)
FIGURE 14. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
FIGURE 16. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 20. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 26. IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022

List of Tables

TABLE 1. IMMUNE CHECKPOINT INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 10. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SOLID CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 22. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 48. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 53. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 75. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 80. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 90. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 120. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 132. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 136. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 141. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 146. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 151. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 156. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 163. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 166. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 178. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 181. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 186. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 188. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 191. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 208. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 209. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 211. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 238. IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 239. IMMUNE CHECKPOINT INHIBITORS MARKET LICENSE & PRICING

Companies Mentioned

Alphamab Oncolog
ALX Oncology Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
BioNTech SE
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb
Dr. Reddy’s Laboratories Ltd.
F. Hoffmann-La Roche AG
Genmab A/S
GlaxoSmithKline PLC
ImmuneSensor Therapeutics Inc.
ImmunityBio, Inc.
Kintor Pharmaceutical Limited
Merck KGaA
MiNK Therapeutics, Inc.
NATCO Pharma Ltd.
NextCure, Inc.
Regeneron Pharmaceuticals Inc.
Sanofi SA
Seagen Inc.
SQZ Biotechnologies Company
Thermo Fisher Scientific Inc.
Xencor, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	190
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 10.46 Billion
Forecasted Market Value ( USD ) by 2030	$ 19.46 Billion
Compound Annual Growth Rate	10.8%
Regions Covered	Global
No. of Companies Mentioned	26

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3259EUR$3,374USD£2,789GBP €3621EUR$3,749USD£3,099GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4128EUR$4,274USD£3,533GBP €4587EUR$4,749USD£3,925GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€4997EUR$5,174USD£4,276GBP €5552EUR$5,749USD£4,752GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5866EUR$6,074USD£5,020GBP €6518EUR$6,749USD£5,578GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7605EUR$7,874USD£6,508GBP €8450EUR$8,749USD£7,231GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Immune Checkpoint Inhibitors - Global Strategic Business Report

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2024-2032

Immune Checkpoint Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Immune Checkpoint Inhibitors Market By Type, By Application: Global Opportunity Analysis and Industry Forecast, 2023-2032

About the Immune Checkpoint Inhibitor Market